Review article · 2026 · Open access
Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 18(3), e70067 · Published 1 May 2026 · DOI 10.1002/wnan.70067
In brief
“Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer” is a 2026 review article by Valeria Bincoletto and 5 co-authors, published in Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology.
- Citations
- 0
- References
- 121
- Authors
- 6
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive cancers, with a poor prognosis due to late diagnosis and resistance to chemotherapy. Gemcitabine (GEM) monotherapy was the gold standard treatment for PDAC until the early 2010s, when two combinatorial therapies, FOLFIRINOX and GEM combined with Nab-paclitaxel, showed the benefits of the multi-drug approach and became the reference treatments for PDAC. Despite their undisputed efficacy, the overall survival of treated PDAC patients is very low, reaching approximately 12% at 5 years, and the side effects of these therapeutic protocols remain severe and not tolerated by all patients. Recent advances in understanding PDAC biology have led to new therapeutic strategies, including new drug combinations and nanomedicine. This review summarizes background information about past and present PDAC therapeutic regimens with their benefits and the drawbacks including the appearance of treatment resistance and focuses on two potential strategies to counteract the limitations of the actual therapies. First, we highlight the interest of combining disulfiram, a repurposed anti-alcoholism drug, with GEM, based on evidence of synergism between the two molecules. We then emphasize the use of drug delivery nanosystems for their ability to improve drug stability, targeting and to potentially overcome resistance and reduce side effects. Finally, we discuss the combination of multi-drug therapies and nanomedicine through the design of apposite drug delivery nanocarriers capable of encapsulating more than one drug and ensuring sustained release. This all-in-one approach should be promising for more effective therapies of this challenging disease. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Biology-Inspired Nanomaterials > Lipid-Based Structures.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bincoletto, V., Andreana, I., Stella, B., Modjtahedi, N., Arpicco, S., & Urbinati, G. (2026). Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 18(3), e70067. https://doi.org/10.1002/wnan.70067
MLA 9
Bincoletto, Valeria, et al. “Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 18, no. 3, 2026, p. e70067. https://doi.org/10.1002/wnan.70067.
Chicago
Bincoletto, Valeria, Ilaria Andreana, Barbara Stella, Nazanine Modjtahedi, Silvia Arpicco, and Giorgia Urbinati. 2026. “Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 18 (3): e70067. https://doi.org/10.1002/wnan.70067.
Harvard
Bincoletto, V. et al. (2026) ‘Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer’, Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 18(3), p. e70067. doi:10.1002/wnan.70067.
IEEE
V. Bincoletto, I. Andreana, B. Stella, N. Modjtahedi, S. Arpicco, and G. Urbinati, “Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer,” Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, vol. 18, no. 3, p. e70067, 2026, doi: 10.1002/wnan.70067.
BibTeX
@article{bincoletto2026breaking,
title = {{Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer}},
author = {Bincoletto, Valeria and Andreana, Ilaria and Stella, Barbara and Modjtahedi, Nazanine and Arpicco, Silvia and Urbinati, Giorgia},
journal = {Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology},
year = {2026},
volume = {18},
number = {3},
pages = {e70067},
doi = {10.1002/wnan.70067},
url = {https://doi.org/10.1002/wnan.70067}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- pancreatic ductal adenocarcinoma
- nanomedicine
- drug delivery nanocarriers
- gemcitabine
- FOLFIRINOX
- nab-paclitaxel
- drug repurposing
- disulfiram
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Bincoletto, V., Andreana, I., Stella, B., Modjtahedi, N., Arpicco, S., & Urbinati, G. (2026). Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 18(3), e70067. https://doi.org/10.1002/wnan.70067
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology: sign in and open the full text from this page.
Who wrote this paper?
Valeria Bincoletto, Ilaria Andreana, Barbara Stella, Nazanine Modjtahedi, Silvia Arpicco, Giorgia Urbinati.
What is the DOI of this paper?
10.1002/wnan.70067, permanently at https://doi.org/10.1002/wnan.70067. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.